[8-K] Protara Therapeutics, Inc. Reports Material Event
On August 11, 2025, Protara Therapeutics, Inc. announced that it released its financial results for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1 to this Form 8-K. The filing explicitly states the press release and related information are being furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other filings unless expressly stated. The 8-K lists Exhibits 99.1 and 104 and is signed by Chief Financial Officer Patrick Fabbio. No financial figures or operating metrics appear in the 8-K text; readers must consult Exhibit 99.1 for the detailed results.
Il 11 agosto 2025 Protara Therapeutics, Inc. ha comunicato di aver pubblicato i risultati finanziari relativi al trimestre chiuso il 30 giugno 2025 tramite un comunicato stampa allegato come Exhibit 99.1 al presente Modulo 8-K. Il documento specifica che il comunicato e le informazioni correlate sono forniti come furnished e non devono essere considerati filed ai sensi dell'Exchange Act né incorporati per riferimento in altri documenti, salvo diversa indicazione. L'8-K elenca gli Exhibits 99.1 e 104 ed è firmato dal Direttore finanziario Patrick Fabbio. Nel testo dell'8-K non sono riportati dati finanziari o indicatori operativi; per i dettagli occorre consultare l'Exhibit 99.1.
El 11 de agosto de 2025, Protara Therapeutics, Inc. anunció que publicó sus resultados financieros correspondientes al trimestre terminado el 30 de junio de 2025 mediante un comunicado de prensa adjunto como Exhibit 99.1 a este Formulario 8-K. La presentación indica expresamente que el comunicado y la información relacionada se presentan como furnished y no deben considerarse filed en virtud del Exchange Act ni incorporarse por referencia en otros documentos, salvo que se indique expresamente lo contrario. El 8-K enumera los Exhibits 99.1 y 104 y está firmado por el Director Financiero Patrick Fabbio. En el texto del 8-K no aparecen cifras financieras ni métricas operativas; los interesados deben consultar el Exhibit 99.1 para ver los resultados detallados.
2025년 8월 11일, Protara Therapeutics, Inc.는 2025년 6월 30일로 종료된 분기 실적을 이 Form 8-K에 첨부된 Exhibit 99.1이라는 보도자료를 통해 발표했다고 밝혔습니다. 해당 제출서류는 보도자료 및 관련 정보가 furnished되었으며 Exchange Act에 따라 filed된 것으로 간주되거나 다른 제출서류에 참조로 통합되지 않는다고 명시하고 있습니다. 이 8-K에는 Exhibit 99.1 및 104가 기재되어 있으며 최고재무책임자(CFO) Patrick Fabbio가 서명했습니다. 8-K 본문에는 재무수치나 영업지표가 포함되어 있지 않으므로 상세 결과는 Exhibit 99.1을 참조해야 합니다.
Le 11 août 2025, Protara Therapeutics, Inc. a annoncé avoir publié ses résultats financiers pour le trimestre clos le 30 juin 2025 via un communiqué de presse joint comme Exhibit 99.1 à ce formulaire 8‑K. Le dépôt précise expressément que le communiqué et les informations associées sont fournis en tant que furnished et ne doivent pas être considérés comme filed au titre de l'Exchange Act, ni incorporés par référence dans d'autres dépôts sauf indication expresse. L'8‑K énumère les Exhibits 99.1 et 104 et est signé par le directeur financier Patrick Fabbio. Aucun chiffre financier ni indicateur opérationnel n’apparaît dans le texte de l’8‑K ; pour les détails, il convient de consulter l’Exhibit 99.1.
Am 11. August 2025 gab Protara Therapeutics, Inc. bekannt, dass das Unternehmen seine Finanzergebnisse für das Quartal zum 30. Juni 2025 in einer Pressemitteilung veröffentlicht hat, die diesem Form 8-K als Exhibit 99.1 beigefügt ist. Die Einreichung weist ausdrücklich darauf hin, dass die Pressemitteilung und die zugehörigen Informationen als furnished übermittelt werden und nicht als filed im Sinne des Exchange Act gelten oder in andere Einreichungen durch Bezugnahme aufgenommen werden, sofern nicht ausdrücklich angegeben. Das 8-K führt die Exhibits 99.1 und 104 auf und ist vom Chief Financial Officer Patrick Fabbio unterzeichnet. Im Text des 8-K sind keine finanziellen Kennzahlen oder operative Messgrößen enthalten; detaillierte Ergebnisse sind dem Exhibit 99.1 zu entnehmen.
- Press release furnished publicly announcing quarter-ended June 30, 2025 results, increasing transparency.
- Form 8-K signed by CFO Patrick Fabbio, indicating authorized corporate disclosure.
- No financial figures or metrics are included in the 8-K text; investors must consult Exhibit 99.1 for actionable data.
- Information is furnished, not filed, so it is not incorporated by reference and carries different legal implications.
Insights
Furnished Q2 2025 results announced; 8-K omits figures—investors must read Exhibit 99.1.
The filing is a routine disclosure that notifies the market a press release with quarterly results exists. Because the 8-K body contains no revenue, earnings, or other operating metrics, the market impact depends entirely on the content of Exhibit 99.1. The furnished status limits Exchange Act Section 18 liabilities, so any review of material changes should focus on the press release itself and subsequent filings that might file those figures.
Routine compliance filing; exhibits identified and signed by CFO, but substantive data is in the attached press release.
The Form 8-K follows standard practice by furnishing a press release and listing the Interactive Data cover page. Signature by the CFO indicates proper internal authorization. The distinction between furnished and filed is important for legal incorporation; governance and disclosure processes appear observed, but material assessment requires the press release content now attached as Exhibit 99.1.
Il 11 agosto 2025 Protara Therapeutics, Inc. ha comunicato di aver pubblicato i risultati finanziari relativi al trimestre chiuso il 30 giugno 2025 tramite un comunicato stampa allegato come Exhibit 99.1 al presente Modulo 8-K. Il documento specifica che il comunicato e le informazioni correlate sono forniti come furnished e non devono essere considerati filed ai sensi dell'Exchange Act né incorporati per riferimento in altri documenti, salvo diversa indicazione. L'8-K elenca gli Exhibits 99.1 e 104 ed è firmato dal Direttore finanziario Patrick Fabbio. Nel testo dell'8-K non sono riportati dati finanziari o indicatori operativi; per i dettagli occorre consultare l'Exhibit 99.1.
El 11 de agosto de 2025, Protara Therapeutics, Inc. anunció que publicó sus resultados financieros correspondientes al trimestre terminado el 30 de junio de 2025 mediante un comunicado de prensa adjunto como Exhibit 99.1 a este Formulario 8-K. La presentación indica expresamente que el comunicado y la información relacionada se presentan como furnished y no deben considerarse filed en virtud del Exchange Act ni incorporarse por referencia en otros documentos, salvo que se indique expresamente lo contrario. El 8-K enumera los Exhibits 99.1 y 104 y está firmado por el Director Financiero Patrick Fabbio. En el texto del 8-K no aparecen cifras financieras ni métricas operativas; los interesados deben consultar el Exhibit 99.1 para ver los resultados detallados.
2025년 8월 11일, Protara Therapeutics, Inc.는 2025년 6월 30일로 종료된 분기 실적을 이 Form 8-K에 첨부된 Exhibit 99.1이라는 보도자료를 통해 발표했다고 밝혔습니다. 해당 제출서류는 보도자료 및 관련 정보가 furnished되었으며 Exchange Act에 따라 filed된 것으로 간주되거나 다른 제출서류에 참조로 통합되지 않는다고 명시하고 있습니다. 이 8-K에는 Exhibit 99.1 및 104가 기재되어 있으며 최고재무책임자(CFO) Patrick Fabbio가 서명했습니다. 8-K 본문에는 재무수치나 영업지표가 포함되어 있지 않으므로 상세 결과는 Exhibit 99.1을 참조해야 합니다.
Le 11 août 2025, Protara Therapeutics, Inc. a annoncé avoir publié ses résultats financiers pour le trimestre clos le 30 juin 2025 via un communiqué de presse joint comme Exhibit 99.1 à ce formulaire 8‑K. Le dépôt précise expressément que le communiqué et les informations associées sont fournis en tant que furnished et ne doivent pas être considérés comme filed au titre de l'Exchange Act, ni incorporés par référence dans d'autres dépôts sauf indication expresse. L'8‑K énumère les Exhibits 99.1 et 104 et est signé par le directeur financier Patrick Fabbio. Aucun chiffre financier ni indicateur opérationnel n’apparaît dans le texte de l’8‑K ; pour les détails, il convient de consulter l’Exhibit 99.1.
Am 11. August 2025 gab Protara Therapeutics, Inc. bekannt, dass das Unternehmen seine Finanzergebnisse für das Quartal zum 30. Juni 2025 in einer Pressemitteilung veröffentlicht hat, die diesem Form 8-K als Exhibit 99.1 beigefügt ist. Die Einreichung weist ausdrücklich darauf hin, dass die Pressemitteilung und die zugehörigen Informationen als furnished übermittelt werden und nicht als filed im Sinne des Exchange Act gelten oder in andere Einreichungen durch Bezugnahme aufgenommen werden, sofern nicht ausdrücklich angegeben. Das 8-K führt die Exhibits 99.1 und 104 auf und ist vom Chief Financial Officer Patrick Fabbio unterzeichnet. Im Text des 8-K sind keine finanziellen Kennzahlen oder operative Messgrößen enthalten; detaillierte Ergebnisse sind dem Exhibit 99.1 zu entnehmen.
FAQ
What did Protara (TARA) disclose in this Form 8-K?
Are the financial results included in the 8-K filing text?
Is the press release in this 8-K considered 'filed' with the SEC?
Which exhibits are referenced in the 8-K?
Who signed the Form 8-K for Protara?
